SETH LERNER to Immunotherapy
This is a "connection" page, showing publications SETH LERNER has written about Immunotherapy.
Connection Strength
0.743
-
Background and Update for S1602 "A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-na?ve High-grade Non-muscle-invasive Bladder Cancer. Eur Urol Focus. 2018 07; 4(4):522-524.
Score: 0.438
-
SIU-ICUD consultation on bladder cancer: basic science. World J Urol. 2019 Jan; 37(1):15-29.
Score: 0.112
-
Bladder cancer. Lancet. 2016 12 03; 388(10061):2796-2810.
Score: 0.094
-
Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer. Urol Oncol. 2009 Mar-Apr; 27(2):155-9.
Score: 0.053
-
Definitions, End Points, and Clinical Trial Designs for Bladder Cancer: Recommendations From the Society for Immunotherapy of Cancer and the International Bladder Cancer Group. J Clin Oncol. 2023 Dec 10; 41(35):5437-5447.
Score: 0.039
-
Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer. J Urol. 2001 Oct; 166(4):1316-21.
Score: 0.008